At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
02137 BRII-B
Closed 12-10 16:08:18
1.600
+0.020
+1.27%
High1.600
Low1.570
Vol1.20M
Open1.580
D1 Closing1.580
Amplitude1.90%
Mkt Cap1.15B
Tradable Cap1.15B
Total Shares721.00M
T/O1.90M
T/O Rate0.17%
Tradable Shares721.00M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
HK Movers | Biotech Stocks Rise. Ascletis up 9%; Antengene up over 5%; Remegen, Laekna, Akeso, Hua Medicine up About 4%
Brii Biosciences Ltd is a biotechnology company principally focused on developing therapies for infectious diseases and central nervous system diseases. The Company's HBV portfolio products include the proprietary therapeutic vaccine BRII-179, the siRNA BRII-835 (elebsiran), and the neutralizing antibody BRII-877 (tobevibart). The Company owns a broad pipeline of multiple innovative drug candidates that focus on infectious diseases and central nervous system diseases. The Company’s products are applied in infectious diseases, such as hepatitis B virus (HBV), human immunodeficiency virus (HIV), multi-drug resistant (MDR) or drug resistant (XDR) gram-negative infections, and other illnesses, such as the central nervous system (CNS) diseases. The Company mainly conducts its businesses in China market.